Knott David M Jr Arcus Biosciences, Inc. Transaction History
Knott David M Jr
- $158 Million
- Q2 2025
A detailed history of Knott David M Jr transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Knott David M Jr holds 70,000 shares of RCUS stock, worth $1.39 Million. This represents 0.36% of its overall portfolio holdings.
Number of Shares
70,000
Previous 12,000
483.33%
Holding current value
$1.39 Million
Previous $94,000
505.32%
% of portfolio
0.36%
Previous 0.06%
Shares
2 transactions
Others Institutions Holding RCUS
# of Institutions
210Shares Held
66.9MCall Options Held
3.18MPut Options Held
167K-
Black Rock Inc. New York, NY9.76MShares$194 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.56MShares$130 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.97MShares$118 Million0.11% of portfolio
-
Woodline Partners LP San Francisco, CA4MShares$79.3 Million0.19% of portfolio
-
Suvretta Capital Management, LLC New York, NY3.69MShares$73.2 Million1.03% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $1.43B
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...